Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | TACR2 | P21452 | 8/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6428470 | 1.00 | ALDH1A1 (0.55) | ALDH1A1TACR2CAPN1KDM4ECNR2 | |
| SCHEMBL7287015 | 0.82 | TACR2 (0.54) | ALDH1A1TACR2KMT2ALMNAMEN1 | |
| SCHEMBL7284529 | 0.79 | ALDH1A1 (0.60) | ALDH1A1TACR2CNR2KMT2AMEN1 | |
| SCHEMBL27463051 | 0.78 | ALDH1A1 (0.66) | ALDH1A1KDM4EKMT2ALMNAMEN1 | |
| SCHEMBL6754301 | 0.77 | MMP8 (0.50) | ALDH1A1TACR2KMT2AMEN1POLB | |
| SCHEMBL6754303 | 0.77 | MMP8 (0.50) | ALDH1A1TACR2KMT2AMEN1POLB | |
| SCHEMBL8060408 | 0.75 | ALDH1A1 (0.53) | ALDH1A1TACR2CNR2KMT2AMEN1 | |
| SCHEMBL8060406 | 0.75 | ALDH1A1 (0.53) | ALDH1A1TACR2CNR2KMT2AMEN1 | |
| SCHEMBL8337939 | 0.75 | POLB (0.53) | ALDH1A1TACR2KMT2ALMNAPOLB | |
| SCHEMBL7408631 | 0.74 | CTSS (0.61) | TACR2KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6888022-B2 | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis | ATHENA NEUROSCIENCES, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-20020052322-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052322-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | APP, BACE1, IAPP | ALDH1A1 3699/4885TACR2 1273/4885CAPN1 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.